Louisiana Woman Blames Pfizer for her Diabetes in Recent Lipitor Lawsuit

Published on April 22, 2014 by Sandy Liebhard

Text-Size:A A A+


A new Lipitor lawsuit has been filed in the U.S. District Court in Philadelphia against the makers of a cholesterol drug that has been allegedly tied to new-onset diabetes, particularly in women.

According to a new report, the suit names Pfizer, Inc. as defendant and includes allegations from a Louisiana plaintiff who was diagnosed with the disease after taking Lipitor from 2006 until 2012. She was originally prescribed the medication to prevent her risk of developing cardiovascular disease by lowering levels of low-density lipoprotein, and was “very healthy” before she started taking the medication, according to Lipitor diabetes claims.

Following her Type 2 diabetes diagnosis in the spring of 2013, the plaintiff in this case must allegedly undergo routine testing of blood glucose levels, as well as adhere to a limited diet and take medication regularly to control the disease, which has resulted in a “markedly increased risk of heart disease, blindness, neuropathy, and kidney disease,” according to her Lipitor lawsuit.

Pfizer Failed to Warn about Lipitor Diabetes Association, Lawsuit Alleges

Among other things, attorneys for the plaintiff in this case accuse Pfizer of having knowledge that the cholesterol-lowering statin may cause Type 2 diabetes, and failing to disclose that information to the public.

Had she known about Lipitor’s association with the disease, lawyers go on to say that the plaintiff would have either opted for a different medication or more closely monitored her glucose levels to stay abreast of changes to her metabolism.

Hers is one of hundreds of similar actions that have been filed against Pfizer. According to a Case List updated on April 15th by the U.S. Judicial Panel on Multidistrict Litigation (JPML), a total of 464 claims have been consolidated in a California federal court proceeding for claims involving the medication. The last time court documents were issued by the Panel, just 270 lawsuits had been filed in the litigation now underway in the U.S. District Court, District of South Carolina. Plaintiffs in these cases similarly allege that Lipitor’s warning label is insufficient in alerting patients of diabetes risks, even after an FDA mandate in February 2012 ordered Pfizer and other stain medications to make note of this side effect.

File a Lipitor Lawsuit Today

Contact our Firm to learn more about Lipitor lawsuits, and whether you may be eligible to file a claim against Pfizer. Call us now at .